Abstract
AIM: To verify the usefulness of FibroQ for predicting fibrosis in patients with chronic hepatitis C, compared with other noninvasive tests. METHODS: This retrospective cohort study included 237 consecutive patients with chronic hepatitis C who had undergone percutaneous liver biopsy before treatment. FibroQ, aspartate aminotransferase (AST)/alanine aminotransferase ratio (AAR), AST to platelet ratio index, cirrhosis discriminant score, age-platelet index (API), Pohl score, FIB-4 index, and Lok's model were calculated and compared. RESULTS: FibroQ, FIB-4, AAR, API and Lok's model results increased significantly as fibrosis advanced (analysis of variance test: P < 0.001). FibroQ trended to be superior in predicting significant fibrosis score in chronic hepatitis C compared with other noninvasive tests. CONCLUSION: FibroQ is a simple and useful test for predicting significant fibrosis in patients with chronic hepatitis C.
| Original language | English |
|---|---|
| Pages (from-to) | 746-753 |
| Number of pages | 8 |
| Journal | World Journal of Gastroenterology |
| Volume | 18 |
| Issue number | 8 |
| DOIs | |
| State | Published - 2012 |
Keywords
- Alanine aminotransferase
- Aspartate aminotransferase
- Aspartate aminotransferase to platelet ratio index
- Fib-4 index
- Fibroq
- Irrhosis discriminant score
- Liver fibrosis
- Lok's model
- Noninvasive test
- Pohl score
